Program
4CMenB vaccine
Also written as “rLP2086”, “rMenB+OMV NZ” and “Meningococcal B vaccine”.
In GlaxoSmithKline's pipeline, Recombinant protein and outer membrance vesicle vaccine
. Its studies are mostly in Meningococcal Infections · Meningitis, Meningococcal · Meningitis · Anemia, Sickle Cell, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 130 open or running | phase 3since Apr 2, 2008 | Feb 27, 2006 | none ahead |
| Pfizer | 90 open or running | phase 4since May 14, 2021 | Oct 11, 2006 | none ahead |
| GlaxoSmithKline | 71 open or running | phase 4since Feb 6, 2018 | Feb 14, 2014 | none ahead |
| Sanofi | 20 open or running | phase 3since Sep 4, 2019 | Sep 4, 2019 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
Men B vaccine GSK3536829
, phase 3, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Feb 27, 2006.
- Feb 14, 2014GlaxoSmithKline's first study: phase 3 study in Meningococcal InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT02106390 · 750 enrolled · Argentina, Mexico
- Jun 5, 2014Phase 3 study in Meningococcal InfectionsGlaxoSmithKline · NCT02173704 · 225 enrolled · Taiwan
- Aug 6, 2014Phase 2 study in Meningococcal InfectionsGlaxoSmithKline · NCT02212457 · 1,063 enrolled · United States, Finland, Poland
- Nov 20, 2014Phase 3 study in Meningitis, MeningococcalNovartis · NCT02305446 · 55 enrolled · Poland
- Apr 26, 2017Phase 3 study in Meningococcal VaccinePfizer · NCT03135834 · 1,610 enrolled · United States, Czechia, Finland and more
- Feb 6, 2018Phase 4 study in Meningitis, MeningococcalGlaxoSmithKline · NCT03493919 · 1,021 enrolled · Australia, Germany
- Sep 4, 2019Sanofi's first study: phase 3 study in Meningococcal Immunisation (Healthy Volunteers)New to SanofiSanofi · NCT04084769 · 570 enrolled · United States, Puerto Rico
- Jun 15, 2020Phase 3 study in Meningococcal VaccinePfizer · NCT04440163 · 2,431 enrolled · United States, Czechia, Denmark and more
- Aug 4, 2020Phase 3 study in Meningococcal InfectionsGlaxoSmithKline · NCT04502693 · 3,657 enrolled · United States, Australia, Canada and more
- Nov 20, 2020Phase 2 study in Meningococcal VaccinePfizer · NCT04645966 · 326 enrolled · Germany, Greece, Spain
- May 14, 2021Phase 4 study in Anemia, Sickle CellPfizer · NCT04893811 · 53 enrolled · Czechia, Poland, Turkey
- Oct 26, 2023Phase 2 study in Meningococcal ImmunisationSanofi · NCT06128733 · 1,215 enrolled · United States, Puerto Rico
- Oct 27, 2023Phase 4 study in Meningitis, MeningococcalGlaxoSmithKline · NCT06113198 · 50 enrolled · South Korea
- May 20, 2025Phase 3 study in MeningitisGlaxoSmithKline · NCT06995430 · 312 enrolled · Finland, Italy, Spain and more
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Recombinant protein and outer membrance vesicle vaccine”the company's pipeline, read by Claude · source
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal gr…”NCIt, read by Claude
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group”NCIt, by rule
Studies
All 31 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06995430Meningitis · Finland, Italy, Spain and more | 3 | Completed | GlaxoSmithKline | Dec 15, 2025 | 312 |
| NCT06113198Meningitis, Meningococcal · South Korea | 4 | Active, not recruiting | GlaxoSmithKline | Sep 7, 2026 | 50 |
| NCT06128733Meningococcal Immunisation · United States, Puerto Rico | 2 | Completed | Sanofi | Aug 27, 2025 | 1,215 |
| NCT04893811Anemia, Sickle Cell · Czechia, Poland, Turkey | 4 | Completed | Pfizer | Sep 6, 2023 | 53 |
| NCT04645966Meningococcal Vaccine · Germany, Greece, Spain | 2 | Terminated | Pfizer | Sep 15, 2022 | 326 |
| NCT04502693Meningococcal Infections · United States, Australia, Canada and more | 3 | Completed | GlaxoSmithKline | Sep 13, 2022 | 3,657 |
| NCT04440163Meningococcal Vaccine · United States, Czechia, Denmark and more | 3 | Completed | Pfizer | Jul 24, 2022 | 2,431 |
| NCT04084769Meningococcal Immunisation (Healthy Volunteers) · United States, Puerto Rico | 3 | Completed | Sanofi | Sep 14, 2020 | 570 |
| NCT03493919Meningitis, Meningococcal · Australia, Germany | 4 | Completed | GlaxoSmithKline | May 27, 2022 | 1,021 |
| NCT03135834Meningococcal Vaccine · United States, Czechia, Finland and more | 3 | Completed | Pfizer | Oct 25, 2022 | 1,610 |
| NCT02305446Meningitis, Meningococcal · Poland | 3 | Completed | Novartis | Apr 2015 | 55 |
| NCT02212457Meningococcal Infections · United States, Finland, Poland | 2 | Completed | GlaxoSmithKline | May 22, 2015 | 1,063 |
| NCT02173704Meningococcal Infections · Taiwan | 3 | Completed | GlaxoSmithKline | Dec 25, 2015 | 225 |
| NCT02106390Meningococcal Infections · Argentina, Mexico | 3 | Completed | GlaxoSmithKline | Oct 14, 2016 | 750 |
| NCT01911221Meningococcal Infections · Germany | 3 | Completed | Novartis | Apr 2014 | 13 |
| NCT01830855Meningococcal Vaccine · United States, Canada, Czech Republic and more | 3 | Completed | Pfizer | Apr 2015 | 3,596 |
| NCT01768117Meningitis, Meningococcal · United States | 2 | Completed | Pfizer | Feb 2014 | 13 |
| NCT01717638Meningococcal Infections · Czech Republic, Italy, Spain and more | 3 | Completed | Novartis | Sep 2013 | 805 |
| NCT01423084Meningococcal Infections · Australia, Canada | 3 | Completed | Novartis | Dec 2011 | 344 |
| NCT01352845Healthy · United States, Canada, Denmark and more | 3 | Completed | Pfizer | Feb 2015 | 3,301 |
| NCT01323270Meningitis · Finland, Germany, Poland | 2 | Completed | Pfizer | Oct 8, 2012 | 753 |
| NCT01214850N. Meningitidis Carriage · United Kingdom | 3 | Completed | Novartis | Jan 2012 | 2,968 |
| NCT01139021Meningococcal Infections · Czech Republic, Finland | 3 | Completed | Novartis | Nov 2010 | 508 |
| NCT01026974Meningococcal Infections · United Kingdom | 2 | Completed | Novartis | Sep 2010 | 120 |
| NCT00944034Meningococcal Infections · Belgium, Czechia, Germany and more | 3 | Completed | Novartis | Aug 2011 | 1,588 |
| NCT00937521Meningitis, Meningococcal · Argentina, Chile, Czech Republic and more | 2 | Completed | Novartis | Nov 2010 | 1,507 |
| NCT00721396Meningococcal Infections · Belgium, Czech Republic, Germany and more | 2 | Completed | Novartis | Jul 2010 | 1,885 |
| NCT00661713Meningococcal Infections · Chile | 3 | Completed | Novartis | Apr 2010 | 1,631 |
| NCT00657709Meningitis, Meningococcal · Austria, Czechia, Finland and more | 3 | Completed | Novartis | Jan 2010 | 3,630 |
| NCT00387725Healthy · Australia | 2 | Completed | Pfizer | Jan 2008 | 127 |
| NCT00297817Meningococcal Infections · United States | 2 | Completed | Novartis | Apr 2007 | 203 |
How it is read
Names in the registry
- “rLP2086”, 11 entries
- “rMenB+OMV NZ”, 9 entries
- “Meningococcal B vaccine”, 6 entries
- “rMenB+OMV NZ vaccine”, 3 entries
- “Meningococcal group B vaccine”, 3 entries
Conditions, from the studies’ own filings
- Meningococcal Infections, 10 studies
- Meningitis, Meningococcal, 9 studies
- Meningitis, 2 studies
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.